

**As submitted to:**

*Journal of Virology*

**And later published as:**

**Functional Macroautophagy Induction by Influenza A  
Virus without a Contribution to Major  
Histocompatibility Complex Class II-Restricted  
Presentation**

**July 2011,p. 6453-6463, Vol. 85, No. 13**

**doi:10.1128/JVI.02122-10**

Joseph D. Comber, Tara M. Robinson, Nicholas A Siciliano, Adam E. Snook and  
Laurence C. Eisenlohr\*

Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas  
Jefferson University, Philadelphia, PA,

Running Title: Role of macroautophagy in MHC class II presentation

\*Corresponding Author. Mailing Address: Thomas Jefferson University, BLSB Room  
730 Philadelphia PA. 19107. Phone: 215-503-4154, Fax: 215-923-4153 Email:  
[Laurence.Eisenlohr@jefferson.edu](mailto:Laurence.Eisenlohr@jefferson.edu)

Abstract word count: 172

Text word count: 5,708

## **ABSTRACT**

MHC class II presented peptides can be derived from both exogenous (extracellular) and endogenous (biosynthesized) sources of antigen. Although several endogenous antigen processing pathways have been reported, little is known about their relative contributions to global CD4<sup>+</sup> T cell responses against complex antigens. Using influenza for this purpose, we assessed the role of macroautophagy, a process in which cytosolic proteins are delivered to the lysosome by de novo vesicle formation and membrane fusion. Influenza infection triggered productive macroautophagy and autophagy-dependent presentation was readily observed with model antigens that naturally traffic to the autophagosome. Furthermore, treatments that enhance or inhibit macroautophagy modulated the level of presentation from these model antigens. However, validated ELISpot assays of influenza-specific CD4<sup>+</sup> T cells from infected

mice using a variety of antigen presenting cells, including primary dendritic cells, revealed no detectable macroautophagy-dependent component. In contrast, the contribution of proteasome-dependent endogenous antigen processing to the global influenza CD4<sup>+</sup> response was readily appreciated. The contribution of macroautophagy to the MHC class II restricted response may vary depending upon the pathogen.

## **INTRODUCTION**

Activation of CD4<sup>+</sup> T cells depends upon their recognition of peptides (epitopes) associated with major histocompatibility class (MHC) class II molecules. Conventionally, peptide generation involves the degradation of exogenous (extracellular) antigens in the endosomal network by multiple mechanisms including unfolding, reduction and proteolytic degradation. It is now clear that epitopes derived from endogenous antigens (synthesized by the cell) can also be presented on MHC class II molecules (12, 22, 24, 38, 49, 50, 60, 66). Indeed, endogenous antigen expression appears to be an absolute requirement for the presentation of some epitopes. For example, UV inactivation of A/PR8/34 influenza virus (PR8) or treatment of infected antigen-presenting cells (APCs) with protein synthesis inhibitors prevents presentation of the NA79 epitope (12). Similar

observations have been made for an epitope derived from influenza matrix protein 1 (24) and an epitope derived from the MHC class I H2-L<sup>d</sup> molecule (39).

Numerous studies have now demonstrated that endogenous antigens can gain access to MHC class II loading compartments via a variety of intracellular pathways (4, 38, 49, 57, 66, 67). Perhaps the most straightforward route is autophagy, in which cytosolic proteins are delivered to the lysosome via several different mechanisms. Chaperone-mediated autophagy results in delivery of cytosolic proteins directly to the lysosome based upon the recognition of a “KFERQ” pentapeptide motif within the target protein, and was shown to be responsible for the presentation of an epitope derived from glutamate decarboxylase (72). Although 30 % of cytosolic proteins contain this motif (70), CMA has not yet been implicated in the class II-restricted response to an infectious agent. Macroautophagy is characterized by the formation of a double membrane structure that engulfs portions of the cytosol including proteins, organelles and/or invading pathogens. The resultant autophagosomes undergo membrane fusion with lysosomes and rapid degradation of the contents ensues (18). Macroautophagic vesicles fuse continuously with class II positive compartments (60) and several epitopes have been shown to depend upon macroautophagy for class II-restricted presentation, including those derived from the C5 protein of the complement pathway (2), neomycin phosphotransferase (45, 53) and the Epstein Barr virus Nuclear Antigen 1 (EBNA-1) (35, 50). Interestingly, EBNA-1 contains two class II-restricted endogenous epitopes that are not autophagy dependent, suggesting that this protein can be processed via more than one pathway (35). Other studies of macroautophagy in antigen processing have employed engineered model antigens in which a well-defined epitope is affixed to a protein that

naturally localizes to the autophagosome. For example, autophagy-dependent presentation was demonstrated for an influenza matrix protein 1 derived epitope fused to the LC3B protein that is involved in autophagosome formation (60).

While a contribution by macroautophagy to class II processing is intuitively appealing, several considerations complicate the picture: 1) In many cases the aggressive proteolysis associated with autophagy may be counterproductive for antigen processing. Presentation of many epitopes is diminished or ablated with elevated endosomal proteolysis (6, 58). Likewise, it has been reported that dendritic cells with reduced endosomal proteolytic activity are more efficient antigen presenters (6, 58). 2) Results that suggest a role for autophagy may have alternative explanations. For example, autophagy was implicated in the class II restricted presentation of antigens derived from nuclear and cytosolic proteins (8) due to the positive effects of serum starvation but this condition also enhances proteasomal activity (14). In addition, gene ablation of a key autophagy component has been reported to impact not just autophagy, but the presentation of exogenous antigens as well (1, 34). 3) Some autophagy substrates may be atypical. For example, EBNA-1 is unusual in containing a Glycine-Alanine (Gly-Ala) repeat region that appears to be involved in immune evasion (36, 37) and also renders the protein prone to aggregation (19, 40) thereby increasing its susceptibility to autophagy (52, 68). 4) Finally, in studying the presentation of class II-restricted epitopes from the influenza neuraminidase and hemagglutinin (HA) glycoproteins, our laboratory has identified an endogenous pathway that depends upon the multicatalytic proteasome, the macromolecular complex that is responsible for most protein turnover within the cytosol and nucleus (13, 17, 20). Remarkably, ELISpot assays revealed that 30-40% of the total

MHC class II restricted response to influenza is specific for proteasome-dependent epitopes (66), a fraction that, when added to the contribution of exogenous processing, may largely discount other processing pathways. Thus, elucidating the relative roles of various processing pathways will require a more global approach.

Here we have taken such a global approach in assessing the CD4<sup>+</sup>T cell responses to influenza virus infection. Although influenza infection activates functional autophagy and we were able to detect autophagy dependent presentation with engineered processing substrates, we could discern no significant contribution of this pathway to the CD4<sup>+</sup>T cell response.

## MATERIALS AND METHODS

**Cells, plasmids and viruses.** L929 fibroblasts stably expressing the H2<sup>d</sup> restricted MHC class II molecule I-Ed (L-IEd) or B6 fibroblasts stably expressing I-Ed and CIITA (B6-IEd) were cultured in DMEM (Mediatech Inc, Manassas, Va) supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, CA) and 1x 2-mercaptoethanol (Invitrogen) at 9% CO<sub>2</sub>. Atg5 wild type or KO fibroblasts were cultured in DMEM supplemented with 10% fetal calf serum 1x non-essential amino acids and maintained at 9% CO<sub>2</sub> (fibroblasts were a kind gift of Dr. David Leib, Dartmouth Medical School). The A20 B cell lymphoma cell line was maintained in IMDM with 10% fetal calf serum and the Raw264.7 cell line was maintained in DMEM with 10% fetal calf serum at 9% CO<sub>2</sub>. A *lacZ* T cell hybridoma specific for the Site-1 epitope of influenza hemagglutinin (62, 66) was used in MUG assays and passaged in RPMI-1640 (Mediatech, Inc) supplemented with 10% fetal calf serum and 1x 2-mercaptoethanol and maintained at 6% CO<sub>2</sub>.

For plasmid generation, the S1 epitope was inserted at the C terminus of Neomycin phosphotransferase or the N terminus of LC3B by PCR using primers that encoded for the S1 epitope at the indicated position. The PCR product was inserted into the pGEM T Easy vector (Thermo Fisher Scientific) and subsequently cloned into the pMSCV vector (generous gift of Dr. Jianke Zhang, Thomas Jefferson University). All DNA constructs were verified by sequencing.

The influenza viruses A/PR/8/34 (PR8; H1N1), A/Japan/305/57 (Jap; H2N2), and B/Lee/40 (B/Lee) were grown as previously described (66). For experiments involving UV virus, live PR8 was diluted in PBS and subjected to UV light for 10 minutes with gentle shaking. Inactivation of the virus was confirmed by staining fibroblasts pulsed

with UV PR8 virus for influenza proteins via flow cytometry. Viral titers were determined using chicken red blood cells and were expressed in hemagglutinin units (HAU). Adenovirus expressing S1LC3 (Ad-S1LC3) was generated by cloning the S1LC3 construct into the pENTR4 entry vector (Invitrogen), followed by subcloning into pAd/CMV/V5-DEST (Invitrogen). Virus was produced in 293A cells (Invitrogen) by transfection with linearized S1LC3-pAd/CMV/V5, followed by expansion and purification with the Adeno-X Purification Kit according to manufacturer's recommendations (BD Biosciences, San Jose CA).

**Mice.** Female BALB/c (H-2<sup>d</sup>) and CB6F1 (H-2<sup>bxd</sup>) mice aged 6-8 weeks were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained at Thomas Jefferson University (Philadelphia PA). Mice were primed intraperitoneally with 100HAU of infectious PR8 or B-Lee diluted in cold PBS or intranasally with 0.1, 0.01, or 0.0001HAU of infectious PR8 in cold PBS. At least 10 days after priming, mice were euthanized using CO<sub>2</sub> and spleens were harvested. CD4<sup>+</sup> T cells were purified using the Dynal magnetic bead negative selection kit according to manufacturer's instruction (Invitrogen) and the purified cells were subsequently used in all ELISpot experiments. All experimental procedures involving mice were approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University.

### **Generation and Retroviral Transduction of Bone Marrow Derived Primary**

**Dendritic Cells.** Bone marrow was isolated from the femurs and tibiae of naïve female BALB/c or CB6F1 mice as previously described (66). Bone marrow was plated in 10cm

culture dishes at  $2 \times 10^6$  cells/plate in a final volume of 10mL of RPMI supplemented with 10%FCS, 1x Penicillin/Streptomycin, 1x L-glutamine, 1x 2ME and GM-CSF (10ng/mL). 48 hours later the cells were harvested, counted and plated in 24 well plates at  $1 \times 10^6$  cells per well. shRNA directed against Atg7 was designed using RNAiCODEX and cloned into the LMP retroviral vector encoding GFP under an IRES promoter (OpenBiosystems, Thermo Fischer Scientific). Retrovirus encoding Atg7shRNA or an empty LMP vector was overlaid onto the primary cells and the cells were spun at 1000g for two hours. After the transduction, fresh growth medium was added to the cells. 48-72 hours after transduction (66) the cells were harvested and sorted for GFP expression for use in ELISpot assays. As in other knockdown experiments, reduction of Atg7 was confirmed by western blotting.

**siRNA Transfections** siRNA against Atg7, Rpt2 or a scrambled control were obtained from Ambion (Applied Biosystems, Austin TX). L-IED fibroblasts were transfected with indicated siRNAs using Amaxa Nucleofection kit V (Lonza, Allendale, NJ) once (48 hours before assay) or twice in a four day period (#1 at day 0; #2 at day 2). B6-IED fibroblasts were transfected with the indicated siRNAs three days prior to assays using RNAiMAX transfection reagent (Invitrogen). A 20 and Raw264.7 cell lines were transfected with siRNA using Amaxa Nucleofection Kit V (Lonza) 48 hours before use (for A20s) or twice within a 48 hour period (for RAW264.7). For the final 24 hours of culture, the Raw264.7 treated with IFN- $\gamma$  to upregulate class II machinery. For siRNA knockdown of the autophagy construct S1LC3, B6-IED fibroblasts stably expressing

S1LC3 were transfected twice within a three day period in order to ensure complete knockdown of preexisting S1pMHC complexes.

**Assessment of autophagy induction and knockdown.** To examine induction of autophagy after influenza virus infection, L-IEE or B6-IEE fibroblasts were infected with PR8 (4-50 HAU/10<sup>6</sup> cells) for 30 minutes at 37°C in PBS/0.1% BSA. At the indicated time points or after an overnight (~16 hours) culture, the cells were trypsinized, washed, and lysed in lysis buffer (100mM NaCl, 100mM Tris pH 8.0, 1% Triton-X) in the presence of HALT protease inhibitor cocktail (Thermo Fischer Scientific) for 15 minutes on ice. Samples were centrifuged for 15 minutes at 13,000g, 4°C to remove debris and protein concentrations were determined by BCA assay (Thermo Fisher Scientific). Equal amounts of protein were loaded onto a 12% SDS gel, subjected to electrophoresis and transferred to a nitrocellulose membrane (GE Healthcare, Piscataway, NJ) membrane for blotting. Anti-LC3b, Anti-Atg7, and anti-actin were obtained from Sigma Aldrich (St Louis, MO).

***In vitro* antigen presentation assays.** B6-IEE fibroblasts were transiently transfected with the indicated constructs using GeneJuice (EMD Biosciences, Gibbstown, NJ). Twenty four hours after transfection, autophagy was induced by treating cells with 200nM rapamycin (EMD Biosciences) overnight. Cells were harvested, fixed with 0.05% PFA (Electron Microscopy Services, Hatfield PA) in 1xHBSS (Thermo Fisher Scientific) for 15 minutes at room temperature, washed extensively and cultured overnight with S1 T hybridomas. T cell activation was assessed by measuring beta-galactosidase activity

using the fluorescent substrate 4-methylumbelliferyl  $\beta$ -D-glucuronide (MUG) with the amount of fluorescence being directly proportional to T cell activation (56, 62).

For chemical inhibition, the autophagy construct S1LC3 was transfected into B6-IED as described above. Twenty four hours later the cells were washed in PBS, acid washed to remove existing pMHC-II complexes from the surface, washed extensively and cultured overnight in the presence of 3MA (Sigma Aldrich) or wortmannin (EMD Biosciences). Cells were harvested and cultured for 6 hours with S1 T hybridomas in a MUG assay. For siRNA mediated inhibition, the autophagy construct S1LC3 was stably transfected into B6-IED and siRNA was transfected as described above. Cells were harvested and cultured with S1 T hybridomas overnight in a MUG assay.

**ELISpots.** L-IED or B6-IED fibroblasts, A20 B cell lymphoma, RAW264.7 macrophages or primary BMDCs were transfected/transduced with the indicated siRNAs or shRNAs. After the optimal time periods for maximal knockdown, the cells were harvested and pulsed with infectious PR8 or UV inactivated PR8 for 30-60 minutes at 37°C in PBS/0.1%BSA. Cells were washed and cultured overnight with purified CD4<sup>+</sup> T cells from the spleens of PR8 primed mice in an IFN- $\gamma$  ELISpot assay. The next day the assay was developed according to manufactures instructions (BD Biosciences). For experiments involving AdenoS1LC3, L-IED fibroblasts were transfected with indicated siRNAs. Six hours after the second transfection, media was changed and the cells were infected with Ad-S1LC3 ( $3 \times 10^8$  IFU/ $0.2 \times 10^6$  cells). 36-48 hours after infection, the infected L-IED fibroblasts were harvested and cultured overnight with purified CD4<sup>+</sup> T cells from a PR8 primed mouse in an IFN- $\gamma$  ELISpot assay. The AdS1LC3 infected L-

IED fibroblasts were also cultured overnight with S1 T hybridomas in a MUG assay. For experiments involving epoxomicin, cells were pretreated with 0.5uM epoxomicin (Enzo Life Sciences, Plymouth Meeting, PA) for 15 minutes prior to infection.

**Statistical Analysis.** Statistics were calculated using a paired Student t Test. p values <0.05 were considered significant.

## RESULTS

**Influenza infection induces functional macroautophagy.** Autophagy can be induced by a variety of viral and bacterial infections (26, 30, 48). Two recent publications reported that influenza virus infection can induce autophagy (15, 73), however one of these indicated that the process is incomplete due to inhibition of vesicular fusion (15). To explore autophagy induction and maturation in our system, L929 fibroblasts stably transfected with the I-Ed $\alpha$  and I-Ed $\beta$  genes (L-IEd) or B6 fibroblasts stably transduced with I-Ed $\alpha$  and I-Ed $\beta$  (B6-IEd) were infected with influenza virus A/PR/8/34 (PR8). As a positive control, the cell lines were treated with the known autophagy inducer rapamycin (47). Autophagy induction was then assessed by measuring the conversion of LC3-I to LC3-II via western blot (41, 55). In both fibroblast lines, PR8 infection induced conversion of LC3-I to LC3-II in a time-dependent manner beginning at 8 hours after infection (Fig. 1a). Treatment of infected cells with Bafilomycin A1, which neutralizes endosomal vesicles, thereby preventing turnover of converted LC3, accentuated this effect (Fig. 1b) indicating that LC3 conversion is not an artifact of increased LC3 synthesis. Inhibition of autophagy via siRNA targeting Atg7, a ubiquitin ligase-like protein essential for autophagosome expansion, resulted in decreased LC3-II accumulation compared to control cells in response to influenza virus infection (Fig. 1c). Atg7 siRNA had a similar impact when rapamycin was used to induce autophagy (data not shown).

To determine whether macroautophagy progressed to maturation we generated B6-IEd fibroblasts that stably express a GFP-LC3 fusion construct (42). Autophagy induction via PR8 infection in B6-IEd-GFP-LC3 cells resulted in a significant decrease in

GFP fluorescence (Fig. 2a left panel), reflecting successful fusion of the autophagosome and destruction of the contents (61). Reduction in fluorescence was not observed in cells expressing unconjugated GFP (Fig. 2a right panel). Furthermore, chemical inhibition of autophagy via wortmannin prevented the reduction of GFP levels after influenza virus infection (Fig. 2b) as well as the accumulation of endogenous LC3-II (Fig. 2c). In addition, PR8 infection of L-IEd fibroblasts resulted in decreased levels of p62, a protein specifically degraded by the autophagy pathway (51) (data not shown). Together these results indicate that the cell lines used for subsequent experiments are capable of being induced to functional autophagy by influenza infection and that our methods of silencing this process are effective.

### **Autophagy can contribute to the presentation of endogenous antigens on MHC class**

**II molecules.** We next determined whether autophagy can deliver endogenous antigens for epitope presentation to CD4<sup>+</sup> T cells as has been previously described (8, 23, 34, 45, 50, 53). To this end, we appended the classically presented H2-IEd restricted Site 1 (S1) epitope of influenza hemagglutinin, which appears to have innate resistance to endocytic proteases (3, 11) to two proteins that have been well described to localize naturally to the autophagosome. S1-conjugated neomycin phosphotransferase (C-terminal attachment) or S1-conjugated LC3B (N-terminal attachment) were transiently transfected into B6-IEd fibroblasts and S1 presentation was assessed using S1-specific T cell hybridomas. As shown in Figure 3, the S1 epitope was presented efficiently from both constructs compared to mock transfected controls. T cell stimulation was enhanced when cells expressing either construct were treated with rapamycin, consistent with an autophagy dependent mechanism of presentation. The more dramatic response of the S1LC3

construct is likely due to LC3B being a specific component of the autophagy pathway whereas NeoS1 is an autophagy substrate that may be less efficiently incorporated into the autophagosome.

Overnight treatment of S1LC3 expressing cells with the chemical inhibitors of autophagy 3MA or wortmannin significantly reduced the presentation of the S1 epitope from B6-IEE fibroblasts (Fig. 4a). 3MA treatment inhibited S1 presentation to a greater extent than wortmannin; however it was also observed to be more toxic to the cells in culture (data not shown). Atg7 siRNA transfection of B6IEE cells stably expressing S1LC3 also resulted in decreased S1 presentation compared to control siRNA transfected cells (Fig. 4b). Additionally, we mutated the glycine at residue 120 of LC3 to an alanine, which prevents LC3 conversion (25). This substantially reduced S1 presentation from the fusion protein (see Fig. S1 in the supplemental material).

### **Establishing a system to assess the contribution of autophagy to the CD4<sup>+</sup> T cell**

**response to influenza.** To determine the contribution of autophagy to the *in vivo* influenza-specific CD4<sup>+</sup> T cell responses, we elected to use an assay that we previously developed for assessing the influence of proteasome activity on the magnitude of the CD4<sup>+</sup> T cell response (66). This involved infection of wild-type mice and analyzing the resulting CD4<sup>+</sup> T cell response with an interferon- $\gamma$  ELISpot in which influenza-infected stimulator cells were treated with or without proteasome inhibitor. The difference in spot number reflected the number of T cells specific for proteasome-dependent epitopes. Even if proteasome deficient mice had been available, we would have chosen this configuration rather than comparing responses in infected wild-type and knockout mice. Our rationale was that the limited homeostatic space might have allowed greater and

lesser quantities of naïve T cells in the wild-type and knockout mice to expand to the same absolute numbers. Thus, although mice have been generated with autophagy deficiencies in certain cell types (34), we opted to dissect the response that occurs in wild-type mice. Aiding this decision was the report that DCs from these knockout mice appear to be impaired in exogenous antigen processing as well (34). To ensure that the assay was sufficiently sensitive, we determined the change in the responding T cell population that can be statistically detected. BALB/c mice were primed with either PR8 or B-Lee influenza viruses which are immunologically distinct. Ten days after priming, CD4<sup>+</sup> T cells were isolated from the spleens, mixed in different proportions and cultured with L-IEed fibroblasts infected with either PR8 or B-Lee virus. Antigen specific CD4<sup>+</sup> T cell responses above background were detected when 10% of the total T cell population was specific for the restimulating virus (see Fig. S2 in the supplemental material).

Also in preparation for analysis of the *in vivo* response, we constructed a positive control adenovirus that expresses S1LC3 (Adeno-S1LC3). We immunized mice intranasally with live PR8 virus and at least 10 days after immunization isolated CD4<sup>+</sup> T cells from the spleen via negative selection. Under these conditions, the S1 epitope is immunodominant (21). The CD4<sup>+</sup> T cells isolated from influenza primed mice were cultured with siRNA transfected L-IEed fibroblasts infected with Adeno-S1LC3 virus. Because only S1 is shared between the two viruses, only S1 specific T cells respond in the assay. Atg7 knockdown in Adeno-S1LC3 infected L-IEed fibroblasts significantly reduced the number of responding CD4<sup>+</sup> T cells in an IFN- $\gamma$  ELISpot assay (Fig. 4c). A decrease in S1 specific T cell activation in an *in vitro* T hybridoma assay (Fig. 4d) was also observed. Together, these results demonstrate that ELISpot assays are capable of

detecting with considerable sensitivity a CD4<sup>+</sup> T cell population specific for autophagy-dependent epitopes expressed in the context of a viral infection.

**Proteasomal activity, but not autophagy, contributes to global MHC class II restricted presentation in an influenza virus infection.** Having observed that influenza does induce functional autophagy, and having validated various aspects of our approach, we asked whether macroautophagy plays an appreciable role in the global CD4<sup>+</sup> T cell response to this complex antigen. L-IEd or B6-IEd fibroblasts were transfected with control or Atg7 specific siRNA, infected with live PR8 virus, and cultured with purified CD4<sup>+</sup> T cells from influenza primed mice in IFN- $\gamma$  ELISpot assays. Under these conditions, more than 90% of the restimulating fibroblasts were infected with PR8 virus (see Fig S3 in the supplemental material). If macroautophagy plays a major role in the generation of MHC class II-restricted influenza-derived epitopes *in vivo*, then CD4<sup>+</sup> T cells that recognize autophagy-dependent epitopes will have been induced, and inhibition of this pathway should result in a decrease in the number of responding CD4<sup>+</sup> T cells in the ELISpot assay. However, despite validation of knockdown (Fig. 4c) and sensitivity of the assay, Atg7 siRNA had no detectable effect on the number of responding CD4<sup>+</sup> T cells (Fig. 5a-d). Similar results were obtained utilizing intraperitoneal or intranasal routes of immunization and also when limiting doses of influenza were used both for priming and for infection of the antigen presenting cells (Fig 5a vs. c and 5b vs. d. and data not shown). When utilized as stimulators in the ELISpot assay, the A20 B cell lymphoma line, the Raw264.7 macrophage cell line, (see Fig. S4 in the supplementary material) and fibroblasts deficient in the autophagy protein Atg5 (data not shown) yielded similar results.

To address the possibility that experimental conditions bias the response towards exogenously processed epitopes, thereby masking contributions by endogenously presented epitopes, stimulators were pulsed with equivalent doses of infectious or UV-inactivated influenza virus. An appreciably greater number of CD4<sup>+</sup> T cells were activated in response to live virus stimulation, indicating that endogenous epitopes are well-represented in the ELISpot assays (See Fig S5 in the supplemental material). We further investigated possible masking effects by eliminating the response to the glycoproteins (HA and NA) which are major targets of the CD4<sup>+</sup> T cell response (below), and which, by virtue of their membrane tethering, are not expected to be substrates for autophagy. This was accomplished by stimulating PR8 (H1N1)-primed CD4<sup>+</sup> T cells in the ELISpot assay with JAP (H2N2)-infected L-IEEd fibroblasts, thereby restricting the response to the untethered internal and non-structural proteins that are virtually identical in all influenza A viruses. This heterologous restimulation reduces the total number of responding T cells by ~ 50% compared to PR8 restimulation (see Fig S5 in the supplemental material). However, autophagy inhibition using Atg7 siRNA does not significantly reduce the number of responding T cells after JAP restimulation. Thus, a substantial portion of the CD4<sup>+</sup> T cell response is directed against internal proteins whose epitopes are produced principally, if not completely, by processes other than autophagy.

DCs play a major role in priming both class I- and class II- restricted responses *in vivo* and it was possible that DCs are more active in macroautophagy than the ELISpot stimulator cells that had been tested and/or are distinct in their selection of autophagy substrates. To address this concern, BMDCs were transduced with the shRNA retroviral vector LMP or LMP encoding an shRNA for Atg7. 48-72 hours after transduction,

BMDCs were sorted for high GFP expression, infected with PR8 virus, and cultured with CD4<sup>+</sup> T cells purified from influenza virus infected mice in an IFN- $\gamma$  ELISpot assay. Flow cytometry confirmed synthesis of viral proteins within DCs pulsed with infectious virus but not equivalent amounts of UV inactivated virus, indicating availability of endogenous antigens (see Fig S3 in the supplemental material and data not shown). Furthermore, stimulation of influenza specific CD4<sup>+</sup> T cells with DCs infected with live virus resulted in higher amounts of T cell activation than when UV inactivated virus was used (data not shown), again indicating that the a substantial portion of the class II response is directed against endogenous epitopes. Knockdown of Atg7 in GFP<sup>hi</sup> cells was substantial (Fig 6A) and this resulted in functionally impaired autophagy as reflected by p62 accumulation (Fig 6B). As with all the other cell types tested,, these primary DCs demonstrated no significant contribution of the macroautophagy pathway *to in vivo* CD4<sup>+</sup> T cell activation (Fig 6C). Importantly, in contrast to Atg5 deficient DCs (34), the presentation of exogenous antigens in our system was not affected (see Fig S6 A,B in supplemental material).

As previously reported (66), treatment of stimulatory APCs with the proteasome inhibitor epoxomicin resulted in a significant decrease in the number of CD4<sup>+</sup> T cells responding in the ELISpot assay (Fig. 7a, b). This was not due to non-specific effects of epoxomicin as presentation of synthetic peptide and the classically presented S1 epitope were not affected. Additionally, while inhibition of protein translation is a potential off-target effect of proteasome inhibitors, production of influenza proteins was only marginally inhibited (see Fig. S7 in the supplemental material). In order to further substantiate the contribution of proteasome-dependent processing and to obtain a closer

comparison with our autophagy related results we carried out siRNA knockdown of Rpt2, an ATPase subunit of the 19S regulatory cap of the proteasome (54). The impact on the ELISpot assay was comparable to that of epoxomicin treatment (without an effect on protein synthesis), while siRNA inhibition of Atg7 again had no effect (Fig. 7c,d).

In summary, although we were able to demonstrate autophagy dependent presentation of individual epitopes, both after transfection and viral infection, we were unable to detect a significant contribution of this pathway to the global presentation of class II restricted epitopes derived from influenza virus infection. At the same time, we did observe a significant contribution of the proteasome dependent pathway to the global class II-restricted response using two different approaches. These results reinforce the notion that, at least for influenza virus, the majority of the endogenous epitopes presented on MHC class II are processed via proteasome-dependent pathway(s).

## DISCUSSION

With recent work highlighting the potential for macroautophagy to orchestrate endogenous MHC class II-restricted presentation of individual antigens(16, 35, 44, 45, 50, 60), our goal was to determine the role in the CD4<sup>+</sup> T cell response to a complex pathogen, specifically influenza. We focused upon this virus due to our previous elucidation of a proteasome-dependent endogenous pathway that is responsible for a substantial portion of the class II-restricted response to influenza infection (66). Considering the large contribution that the classical exogenous pathway also makes to the response, we wondered if there would be sufficient opportunity for another major pathway. Before addressing this central question, preliminary work in three general areas was required to validate both the relevance of studying autophagy in the context of an influenza infection and the experimental system that we had selected.

First, although influenza virus infection has been shown to induce LC3 conversion in a number of cell lines, it remains unclear whether functional autophagy, resulting in membrane fusion with active lysosomes, is stimulated (15, 33, 73). It has been reported that influenza infection of human lung epithelial cells prevents autophagosomes from fusing with lysosomes (15) with the viral M2 protein acting as an inhibitor of Beclin-1, a key protein in the autophagy pathway. However, others have concluded that functional autophagy, as measured by the degradation of the autophagy substrate p62, does occur in the face of influenza infection (33). The discrepancies may be due to the cell types and/or the influenza strains that were utilized. As assessed by both GFP-LC3 and p62 degradation, we observed that influenza virus infection does

induce functional macroautophagy in several different cell types, including primary DCs, with no detectable block in the pathway.

Second, using a standard approach in the field, we ascertained our ability to observe macroautophagy dependent antigen processing by tracking presentation of an individual epitope (2, 35, 45, 50). Appending the S1 epitope onto neomycin phosphotransferase or LC3B and expressing the constructs via transfection resulted in autophagy dependent presentation that could be enhanced by inducing autophagy with rapamycin or significantly decreased by chemical and genetic inhibition of the autophagy pathway. We also constructed an adenovirus expressing the S1LC3 fusion protein and obtained similar results.

Third, we utilized a recombinant adenovirus to validate the ELISpot assay that was subsequently used to assess the global contribution of autophagy. Results demonstrated that dependence of a polyclonal T cell population on functionally active autophagy within the APC could be readily appreciated. Because this assay represented a best case scenario in which all of the responding T cells were specific for the autophagy-dependent epitope, we carried out additional assays with heterologous influenza viruses, which confirmed that even minor populations within the pool of primed CD4<sup>+</sup> T cells ( $\leq 10\%$ ) could be detected.

With the general framework of the assay having been validated, analyses could have been carried out in two general ways: 1) Infection of wild-type and autophagy deficient mice (which have autophagy defects in only certain cell types), and subsequent determination of the differences in the CD4<sup>+</sup> T cell responses, or 2) infection of wild-type

mice only, with subsequent identification of the autophagy-dependent component. We chose the latter for two reasons. First, despite possible differences in precursor frequencies, CD4<sup>+</sup> T cells in wild-type and mutant mice might have expanded to the same absolute numbers requiring us to analyze differences by less meaningful criteria, such as T cell receptor diversity. Furthermore, because multiple subsets of antigen presenting cells can initiate an immune response, the selective autophagy knockout system that is currently available would complicate interpretation. In fact, mice that lack the *Atg7* gene only in the hematopoietic stem cell compartment (either due to conditional knockout or reconstitution of an irradiated wild-type mouse with *Atg7* deficient bone marrow) display reduced numbers of multiple immune cell subsets and die within weeks following elimination of this protein(43). Furthermore, recent analysis of *Atg5* deficient DCs from the knockout mice indicates a deficiency in exogenous antigen processing (34). Our results demonstrate that short-term knockdown of autophagy, in contrast, does not have this effect.

Having carried out these preliminary steps, we asked whether macroautophagy plays a major role in the generation of epitopes during influenza virus infection. Despite potent induction of functional autophagy by influenza virus infection and a sufficiently sensitive assay, we detected no significant contribution of this pathway to the global CD4<sup>+</sup> T cell response to influenza virus. This was true of all antigen presenting cell types tested including primary DCs and also when the assay was restricted to the internal and non-structural proteins of the virus. In contrast, as previously reported (66) a substantial portion of the CD4<sup>+</sup> T cell response was observed to be proteasome-dependent by two

independent methods for modulating proteasome activity (chemical inhibition and siRNA treatment).

Several factors may limit the utility of autophagy for class II-restricted epitope generation. Although largely considered a nonselective pathway of protein degradation, recent data suggest that efficient delivery of individual soluble proteins to the autophagosomes is dependent upon a specific recognition mechanism (27, 29, 46). In agreement with this, the S1 epitope is more robustly presented from the S1LC3 construct, which is directly targeted to the autophagy pathway via LC3B, compared to the NeoS1 construct, which is likely targeted by less selective mechanisms. It seems unlikely that individual viral proteins would self target to this compartment, as has been reported in some cases (69), unless it were advantageous. Both poliovirus and rhinovirus induce the formation of double membrane autophagosomes to facilitate replication and autophagy inhibition via siRNA was observed to decrease the amount of poliovirus released from infected cells. Indeed, conditions necessary for processing are likely absent since induced autophagosomes are not mobile and presumably do not fuse efficiently with the late endosome compartment (65). Likewise, hepatitis C virus induces autophagy to initiate the early stages of viral replication (9, 10, 64) but the degradation of autophagy substrates, including p62, is blocked (63).

Once captured by the autophagosome, an epitope must survive in the highly proteolytic environment of the late endosome/lysosome. This may be a losing prospect in many cases. Enhanced proteolytic activity has been reported to be generally detrimental to antigen presentation, consistent with the idea that proteases and empty class II molecules compete for access to unfolded proteins (7, 59). What is more, autophagy

inhibition via siRNA has been reported to reduce cathepsin activity in the late endosome (34), suggesting that fusion of the autophagosome with the endosomal compartment may create an even more aggressive environment. We have previously reported on the negative impact of heightened proteolysis. Presentation of the hemagglutinin-based S3 epitope from exogenous sources of PR8 is enhanced up to ten-fold when endosomal cathepsins are inhibited (3), while the NA79 epitopes appears to be so susceptible to endosomal proteases that presentation from exogenous virus is undetectable in most cases (11, 66). In contrast to S1, neither of these epitopes was presented when appended to neomycin phosphotransferase with or without rapamycin treatment (data not shown), suggesting that they are immediately destroyed upon delivery to the autophagosome. Thus, only those class II-restricted epitopes that are sufficiently resistant to endolysosomal proteolysis, may be candidates for autophagy mediated presentation.

We cannot rule out the possibility that there is a small autophagy-dependent fraction of the class II-restricted influenza response that is below the detection limit of our assays. In our system, we determined the sensitivity of the ELISpot assay to detect antigen specific T cells to be <10%, suggesting that if autophagy does play a role in the class II response, the contribution is minimal. In addition we cannot discount the possibility that epitopes are generated via parallel pathways such that inhibition of autophagy would shift the substrate to other processing routes.

In preliminary experiments the global class II responses to vaccinia and adenovirus infections are also not substantially altered by inhibition of autophagy (J.D.C. unpublished observations). We are, nevertheless, cautious about generalizing these findings to other viruses. All three of the viruses that have been tested mediate acute and

limiting infections in mice. In contrast, herpes viruses such as EBV are generally chronic and evasion from CD8<sup>+</sup> T cell recognition appears to be a major priority (5). The EBNA-1 protein contributes directly to this effort by blocking proteasomal degradation and subsequent MHC class I restricted presentation via an N-terminal Gly-Ala repeat (36, 37). Other herpes viruses encode proteins with similar functions (31, 71). Inhibition of the proteasome induces aggregate formation which may shift the balance of global protein degradation towards the autophagy pathway (28, 32, 68). Thus similar analyses of viruses with fundamentally different replication strategies are warranted

## **ACKNOWLEDGMENTS**

This work was supported by the National Institutes of Health Grant R01AI069192 to L.C.E.

The authors would like to Dr. Christopher Snyder, Dr. James Testa, Dr. Nancy Luckashenak, and Michael Miller for helpful comments and suggestions during the preparation of the manuscript and Dr. Michael Bevan (University of Washington) for providing reagents.. We would also like to thank the Department of Biostatistics, Thomas Jefferson University (Philadelphia, PA) for help with statistical analysis.

## REFERENCES

1. **Blanchet, F., A. Moris, D. Nikolic, M. Lehmann, S. Cardinaud, R. Stalder, E. Garcia, C. Dinkins, F. Leuba, L. Wu, O. Schwartz, V. Deretic, and V. Piguet.** 2010. Human Immunodeficiency Virus-1 Inhibition of Immunoamphisomes in Dendritic Cells Impairs Early Innate and Adaptive Immune Responses. *Immunity*. .
2. **Brazil, M., S. Weiss, and B. Stockinger.** 1997. Excessive degradation of intracellular protein in macrophages prevents presentation in the context of major histocompatibility complex class II molecules. *Eur. J. Immunol.* **27**:1506-1506-14.
3. **Chianese-Bullock, K. A., H. I. Russell, C. Moller, W. Gerhard, J. J. Monaco, and L. C. Eisenlohr.** 1998. Antigen Processing of Two H2-IEd-Restricted Epitopes Is Differentially Influenced by the Structural Changes in a Viral Glycoprotein. *J. Immunol.* **161**:1599-1607.
4. **Crotzer, V., and J. Blum.** 2008. Cytosol to lysosome transport of intracellular antigens during immune surveillance. *Traffic.* **9**:10-10-6.
5. **Davis-Poynter, N., and H. Farrell.** 1996. Masters of deception: a review of herpesvirus immune evasion strategies. *Immunol. Cell Biol.* **74**:513-513-22.
6. **Delamarre, L., R. Couture, I. Mellman, and E. S. Trombetta.** 2006. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. *The Journal of Experimental Medicine.* **203**:2049-2055. doi: 10.1084/jem.20052442.
7. **Delamarre, L., M. Pack, H. Chang, I. Mellman, and E. S. Trombetta.** 2005. Differential Lysosomal Proteolysis in Antigen-Presenting Cells Determines Antigen Fate. *Science.* **307**:1630-1634. doi: 10.1126/science.1108003.

8. **Dengjel, J., O. Schoor, R. Fischer, M. Reich, M. Kraus, M. Müller, K. Kreymborg, F. Altenberend, J. Brandenburg, H. Kalbacher, R. Brock, C. Driessen, H. Rammensee, and S. Stevanovic.** 2005. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. *Proceedings of the National Academy of Sciences of the United States of America.* **102**:7922-7927. doi: 10.1073/pnas.0501190102.
9. **Dreux, M., and F. Chisari.** 2009. Autophagy proteins promote hepatitis C virus replication. *Autophagy.* **5**:1224-1224-5. doi: 10.1073/pnas.0907344106.
10. **Dreux, M., P. Gastaminza, S. F. Wieland, and F. V. Chisari.** 2009. The autophagy machinery is required to initiate hepatitis C virus replication. *PNAS.* **106**:14046-14051. doi: 10.1073/pnas.0907344106.
11. **Eisenlohr, L., W. Gerhard, and C. Hackett.** 1988. Individual class II-restricted antigenic determinants of the same protein exhibit distinct kinetics of appearance and persistence on antigen-presenting cells. *J. Immunol.* **141**:2581-2584.
12. **Eisenlohr, L., and C. Hackett.** 1989. Class II major histocompatibility complex-restricted T cells specific for a virion structural protein that do not recognize exogenous influenza virus. Evidence that presentation of labile T cell determinants is favored by endogenous antigen synthesis. *J. Exp. Med.* **169**:921-931. doi: 10.1084/jem.169.3.921.
13. **Finley, D.** 2009. Recognition and processing of ubiquitin-protein conjugates by the proteasome. *Annu. Rev. Biochem.* **78**:477-477-513.
14. **Fuertes, G., J. Martin De Llano, A. Villarroya, A. Rivett, and E. Knecht.** 2003. Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts

produced by serum withdrawal, amino-acid deprivation and confluent conditions.

Biochem. J. **375**:75-75-86.

15. **Gannage, M., D. Dormann, R. Albrecht, J. Dengjel, T. Torossi, P. Ramer, M. Lee, T. Strowig, F. Arrey, G. Conenello, M. Pypaert, J. Andersen, A. Garcia-Sastre, and C. Munz.** 2009. Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. *Cell Host Microbe*. **6**:367-367-80.
16. **Gannage, M., and C. Munz.** 2009. Autophagy in MHC class II presentation of endogenous antigens. *Curr. Top. Microbiol. Immunol.* **335**:123-123-40.
17. **Glickman, M. H., and A. Ciechanover.** 2002. The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction. *Physiol. Rev.* **82**:373-428.
18. **He, C., and D. Klionsky.** 2009. Regulation mechanisms and signaling pathways of autophagy. *Annu. Rev. Genet.* **43**:67-67-93.
19. **Hennessy, K., and E. Kieff.** 1983. One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. *Proceedings of the National Academy of Sciences of the United States of America.* **80**:5665-5669.
20. **Hershko, A., and A. Ciechanover.** 1998. The ubiquitin system. *Annu. Rev. Biochem.* **67**:425-425-79.
21. **Hurwitz, J., E. Herber-Katz, C. Hackett, and W. Gerhard.** 1984. Characterization of the murine TH response to influenza virus hemagglutinin: evidence for three major specificities. *J. Immunol.* **133**:3371-3377.
22. **Jacobson, S., R. P. Sekaly, C. L. Jacobson, H. F. McFarland, and E. O. Long.** 1989. HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. *J. Virol.* **63**:1756-1762.

23. **Jagannath, C., D. Lindsey, S. Dhandayuthapani, Y. Xu, R. Hunter, and N. Eissa.** 2009. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. *Nat. Med.* **15**:267-267-76.
24. **Jaraquemada, D., M. Marti, and E. Long.** 1990. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. *J. Exp. Med.* **172**:947-954. doi: 10.1084/jem.172.3.947.
25. **Kabeya, Y., N. Mizushima, T. Ueno, A. Yamamoto, T. Kirisako, T. Noda, E. Kominami, Y. Ohsumi, and T. Yoshimori.** 2000. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *EMBO J.* **19**:5720-5720-8.
26. **Kirkegaard, K.** 2009. Subversion of the cellular autophagy pathway by viruses. *Curr. Top. Microbiol. Immunol.* **335**:323-323-33.
27. **Klionsky, D.** 2007. Autophagy: from phenomenology to molecular understanding in less than a decade. *Nat. Rev. Mol. Cell Biol.* **8**:931-931-7.
28. **Kopito, R.** 2000. Aggresomes, inclusion bodies and protein aggregation. *Trends Cell Biol.* **10**:524-524-30.
29. **Korolchuk, V., F. Menzies, and D. Rubinsztein.** 2010. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. *FEBS Lett.* **584**:1393-1393-8.
30. **Kudchodkar, S., and B. Levine.** 2009. Viruses and autophagy. *Rev. Med. Virol.* **19**:359-359-78.
31. **Kwun, H. J., S. R. da Silva, I. M. Shah, N. Blake, P. S. Moore, and Y. Chang.** 2007. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1

Mimics Epstein-Barr Virus EBNA1 Immune Evasion through Central Repeat Domain Effects on Protein Processing. *J. Virol.* **81**:8225-8235. doi: 10.1128/JVI.00411-07.

32. **Lamark, T., and T. Johansen.** 2010. Autophagy: links with the proteasome. *Curr. Opin. Cell Biol.* **22**:192-192-8.

33. **Law, A., D. Lee, K. Yuen, M. Peiris, and A. Lau.** 2010. Cellular response to influenza virus infection: a potential role for autophagy in CXCL10 and interferon-alpha induction. *Cell Mol Immunol.* .

34. **Lee, H., L. Mattei, B. Steinberg, P. Alberts, Y. Lee, A. Chervonsky, N. Mizushima, S. Grinstein, and A. Iwasaki.** 2010. In vivo requirement for Atg5 in antigen presentation by dendritic cells. *Immunity.* **32**:227-227-39.

35. **Leung, C. S., T. A. Haigh, L. K. Mackay, A. B. Rickinson, and G. S. Taylor.** 2010. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. *Proceedings of the National Academy of Sciences.* **107**:2165-2170. doi: 10.1073/pnas.0909448107.

36. **Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. Steigerwald-Mulle..., G. Klein, M. Kurilla, and M. Masucci.** 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. *Nature.* **375**:685-685-8.

37. **Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M. G. Masucci.** 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. *Proceedings of the National Academy of Sciences of the United States of America.* **94**:12616-12621.

38. **Lich, J. D., J. F. Elliott, and J. S. Blum.** 2000. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. *J Exp Med.* **191**:1513-1524.
39. **Loss, G. E., C. G. Elias, P. E. Fields, R. K. Ribaldo, M. McKisic, and A. J. Sant.** 1993. Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways. *The Journal of Experimental Medicine.* **178**:73-85. doi: 10.1084/jem.178.1.73.
40. **Luka, J., T. Lindahl, and G. Klein.** 1978. Purification of the Epstein-Barr virus-determined nuclear antigen from Epstein-Barr virus-transformed human lymphoid cell lines. *J. Virol.* **27**:604-611.
41. **Mizushima, N., and T. Yoshimori.** 2007. How to interpret LC3 immunoblotting. *Autophagy.* **3**:542-542-5.
42. **Mizushima, N., A. Yamamoto, M. Matsui, T. Yoshimori, and Y. Ohsumi.** 2004. In Vivo Analysis of Autophagy in Response to Nutrient Starvation Using Transgenic Mice Expressing a Fluorescent Autophagosome Marker. *Mol. Biol. Cell.* **15**:1101-1111. doi: 10.1091/mbc.E03-09-0704.
43. **Mortensen, M., E. J. Soilleux, G. Djordjevic, R. Tripp, M. Lutteropp, E. Sadighi-Akha, A. J. Stranks, J. Glanville, S. Knight, S. W. Jacobsen, K. R. Kranc, and A. K. Simon.** 2011. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. *J. Exp. Med.* **208**:455-467. doi: 10.1084/jem.20101145.
44. **Munz, C.** 2009. Enhancing immunity through autophagy. *Annu. Rev. Immunol.* **27**:423-423-49.

45. **Nimmerjahn, F., S. Milosevic, U. Behrends, E. Jaffee, D. Pardoll, G. Bornkamm, and J. Mautner.** 2003. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. *Eur. J. Immunol.* **33**:1250-1250-9.
46. **Noda, N., Y. Ohsumi, and F. Inagaki.** 2010. Atg8-family interacting motif crucial for selective autophagy. *FEBS Lett.* **584**:1379-1379-85.
47. **Noda, T., and Y. Ohsumi.** 1998. Tor, a Phosphatidylinositol Kinase Homologue, Controls Autophagy in Yeast. *Journal of Biological Chemistry.* **273**:3963-3966. doi: 10.1074/jbc.273.7.3963.
48. **Ogawa, M., and C. Sasakawa.** 2006. Bacterial evasion of the autophagic defense system. *Curr. Opin. Microbiol.* **9**:62-62-8.
49. **Oxenius, A., M. F. Bachmann, P. G. Ashton-Rickardt, S. Tonegawa, R. M. Zinkernagel, and H. Hengartner.** 1995. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. *Eur J Immunol.* **25**:3402-3411.
50. **Paludan, C., D. Schmid, M. Landthaler, M. Vockerodt, D. Kube, T. Tuschl, and C. Munz.** 2005. Endogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy. *Science.* **307**:593-596. doi: 10.1126/science.1104904.
51. **Pankiv, S., T. H. Clausen, T. Lamark, A. Brech, J. Bruun, H. Outzen, A. Øvervatn, G. Bjørkøy, and T. Johansen.** 2007. p62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy. *Journal of Biological Chemistry.* **282**:24131-24145. doi: 10.1074/jbc.M702824200.

52. **Ravikumar, B., R. Duden, and D. C. Rubinsztein.** 2002. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. *Hum. Mol. Genet.* **11**:1107-1117. doi: 10.1093/hmg/11.9.1107.
53. **Riedel, A., F. Nimmerjahn, S. Burdach, U. Behrends, G. Bornkamm, and J. Mautner.** 2008. Endogenous presentation of a nuclear antigen on MHC class II by autophagy in the absence of CRM1-mediated nuclear export. *Eur. J. Immunol.* **38**:2090-2090-5.
54. **Rubin, D., M. Glickman, C. Larsen, S. Dhruvakumar, and D. Finley.** 1998. Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome. *EMBO J.* **17**:4909-4909-19.
55. **Rubinsztein, D., A. Cuervo, B. Ravikumar, S. Sarkar, V. Korolchuk, S. Kaushik, and D. Klionsky.** 2009. In search of an "autophagometer". *Autophagy.* **5**:585-585-9.
56. **Sanderson, S., and N. Shastri.** 1994. LacZ inducible, antigen/MHC-specific T cell hybrids. *International Immunology.* **6**:369-376. doi: 10.1093/intimm/6.3.369.
57. **Sant, A.** 1994. Endogenous antigen presentation by MHC class II molecules. *Immunol. Res.* **13**:253-253-67.
58. **Savina, A., and S. Amigorena.** 2007. Phagocytosis and antigen presentation in dendritic cells. *Immunol Rev.* **219**:143-156.
59. **Savina, A., C. Jancic, S. Hugues, P. Guermonprez, P. Vargas, I. Moura, A. Lennon-Dumenil, M. Seabra, G. Raposo, and S. Amigorena.** 2006. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. *Cell.* **126**:205-205-18.

60. **Schmid, D., M. Pypaert, and C. Munz.** 2007. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. *Immunity*. **26**:79-79-92.
61. **Shvets, E., E. Fass, and Z. Elazar.** 2008. Utilizing flow cytometry to monitor autophagy in living mammalian cells. *Autophagy*. **4**:621-621-8.
62. **Sinnathamby, G., and L. C. Eisenlohr.** 2003. Presentation by Recycling MHC Class II Molecules of an Influenza Hemagglutinin-Derived Epitope That Is Revealed in the Early Endosome by Acidification. *J. Immunol.* **170**:3504-3513.
63. **Sir, D., W. Chen, J. Choi, T. Wakita, T. S. Benedict Yen, and J. J. Ou.** 2008. Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response. *Hepatology*. **48**:1054-1061.
64. **Tanida, I., M. Fukasawa, T. Ueno, E. Kominami, T. Wakita, and K. Hanada.** 2009. Knockdown of autophagy-related gene decreases the production of infectious hepatitis C virus particles. *Autophagy*. **5**:937-937-45. doi: 10.1073/pnas.0907344106.
65. **Taylor, M. P., T. B. Burgon, K. Kirkegaard, and W. T. Jackson.** 2009. Role of Microtubules in Extracellular Release of Poliovirus. *J. Virol.* **83**:6599-6609. doi: 10.1128/JVI.01819-08.
66. **Tewari, M., G. Sinnathamby, D. Rajagopal, and L. Eisenlohr.** 2005. A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. *Nat. Immunol.* **6**:287-287-94.
67. **van Luijn, M., M. Chamuleau, M. Rensing, E. Wiertz, S. Ostrand-Rosenberg, Y. Souwer, A. Zevenbergen, G. Ossenkuppele, A. van de Loosdrecht, and S. van Ham.** 2010. Alternative Ii-independent antigen-processing pathway in leukemic blasts involves

TAP-dependent peptide loading of HLA class II complexes. *Cancer Immunol. Immunother.* **59**:1825-1825-38.

68. **Webb, J. L., B. Ravikumar, J. Atkins, J. N. Skepper, and D. C. Rubinsztein.**

2003.  $\alpha$ -Synuclein Is Degraded by Both Autophagy and the Proteasome. *Journal of Biological Chemistry.* **278**:25009-25013. doi: 10.1074/jbc.M300227200.

69. **Wileman, T.** 2006. Aggresomes and Autophagy Generate Sites for Virus Replication. *Science.* **312**:875-878. doi: 10.1126/science.1126766.

70. **Wing, S., H. Chiang, A. Goldberg, and J. Dice.** 1991. Proteins containing peptide sequences related to Lys-Phe-Glu-Arg-Gln are selectively depleted in liver and heart, but not skeletal muscle, of fasted rats. *Biochem. J.* **275 ( Pt 1)**:165-165-9.

71. **Zaldumbide, A., M. Ossevoort, E. Wiertz, and R. Hoeben.** 2007. In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi sarcoma herpes virus. *Mol. Immunol.* **44**:1352-1352-60.

72. **Zhou, D., P. Li, Y. Lin, J. Lott, A. Hislop, D. Canaday, R. Brutkiewicz, and J. Blum.** 2005. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. *Immunity.* **22**:571-571-81.

73. **Zhou, Z., X. Jiang, D. Liu, Z. Fan, X. Hu, J. Yan, M. Wang, and G. Gao.** 2009. Autophagy is involved in influenza A virus replication. *Autophagy.* **5**:321-321-8.